Literature DB >> 11347725

Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited.

E J Wallenstein1, D Fife.   

Abstract

OBJECTIVES: Determine whether recent US adverse event reports for several non-steroidal anti-inflammatory drugs (NSAIDs) conform to the temporal pattern observed by Dr JCP Weber in the UK in the early 1980s, i.e. a rising count in the first few years after launch presumably reflecting increased exposure, followed by a decline, presumably reflecting decreased enthusiasm for reporting as adverse events become well known. STUDY
SETTING: US adverse event report data available from the US Food and Drug Administration, reformatted by a commercial vendor.
METHODS: For the 5 NSAIDs launched in the US between 1987 and 1993 that had data suitable for this study, we tabulated by year from launch the number of reports and the reporting rate (number of reports per 1000 prescriptions).
RESULTS: The number of reports for 3 of the 5 NSAIDs showed a temporal pattern approximating that described by Weber. The number of reports for the other 2 NSAIDs showed temporal patterns markedly different from that described by Weber. For 4 of the 5 NSAIDs, reporting rates did not decline consistently with time from launch. DISCUSSION: The temporal patterns of adverse event reports are more complex than those described in Weber's classic report. The number of reports does not reliably rise and then fall after launch and the reporting rate does not reliably decrease with time from launch.

Mesh:

Substances:

Year:  2001        PMID: 11347725     DOI: 10.2165/00002018-200124030-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  2 in total

1.  Cardiac arrest due to severe hyperkalaemia in patient taking nabumetone and low salt diet.

Authors:  B Pal; A Hutchinson; A Bhattacharya; A Ralston
Journal:  BMJ       Date:  1995-12-02

2.  Agranulocytosis associated with etodolac.

Authors:  R L Cramer; V C Aboko-Cole; R J Gualtieri
Journal:  Ann Pharmacother       Date:  1994-04       Impact factor: 3.154

  2 in total
  16 in total

1.  Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.

Authors:  Guillaume Moulis; Agnès Sommet; Geneviève Durrieu; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions.

Authors:  Matthew S Davenport; Jonathan R Dillman; Richard H Cohan; Hero K Hussain; Shokoufeh Khalatbari; Jonathan B McHugh; James H Ellis
Journal:  Radiology       Date:  2012-12-13       Impact factor: 11.105

3.  Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.

Authors:  David P Kao; Mark C P Haigney; Philip S Mehler; Mori J Krantz
Journal:  Addiction       Date:  2015-09       Impact factor: 6.526

4.  Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

Authors:  Pankdeep Chhabra; Xing Chen; Sheila R Weiss
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

5.  Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.

Authors:  Antoine Pariente; Amélie Daveluy; Anne Laribière-Bénard; Ghada Miremont-Salame; Bernard Begaud; Nicholas Moore
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.

Authors:  Minh-Phuong Huynh-Le; Randall C Shults; Michael J Connor; Jona A Hattangadi-Gluth
Journal:  Clin Genitourin Cancer       Date:  2019-12-05       Impact factor: 2.872

7.  Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers.

Authors:  Elisabet Ekman; Staffan Hägg; Anders Sundström; Viktoria Werkström
Journal:  Drug Healthc Patient Saf       Date:  2010-03-29

8.  The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.

Authors:  Keith B Hoffman; Mo Dimbil; Colin B Erdman; Nicholas P Tatonetti; Brian M Overstreet
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

9.  Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs.

Authors:  Ankur Arora; Rajinder K Jalali; Divya Vohora
Journal:  Ther Clin Risk Manag       Date:  2017-09-11       Impact factor: 2.423

10.  Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database.

Authors:  Anitha Kurian; Kanika Kaushik; Viswam Subeesh; Eswaran Maheswari; Radhika Kunnavil
Journal:  J Reprod Infertil       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.